Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
收藏官方服务：
资源简介：
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
应用场景：
创建时间：
2013-03-07
相关数据集
Analysis of Hadron Therapy Market By Electron Beam, Proton Beam, Neutron Beam, Carbon Ion Beam, Alpha Particle Beam, and Beta Particle Beam 2023 to 2033
The global hadron therapy market is expected to be valued at US$ 1.5 billion in 2023 and reach US$ 4.7 billion by 2033. From 2023 to 2033, the market is estimated at a CAGR of 11.9
www.futuremarketinsights.com2023-08-08 更新100
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) cell line H3K27ac CUT&RUN
Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare form of ovarian cancer affecting young women and girls. Survival rates remain poor despite aggressive treatment of these patient
NIAID Data Ecosystem70
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Super-enhancers (SEs), which are composed of large clusters of enhancers densely loaded with the Mediator complex, transcription factors and chromatin regulators, drive high expression of genes implic
NIAID Data Ecosystem80
Oncofusion driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1 [enhancer knockdown]. Oncofusion driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1 [enhancer knockdown]
Ewing Sarcoma (EwS) is a highly aggressive tumor of bone and soft tissues that mostly affects children and adolescents. The pathognomonic oncofusion EWSR1-ETS (EWS-FLI1/EWSR1-ERG) transcription factor
NIAID Data Ecosystem40
